Apolipoprotein News and Research

RSS

Selective use of DHCA during surgery for CHD in infancy does not impair neurological outcomes

Congenital heart defects (CHD) are the most common birth defects in humans, affecting 8 per 1000 live births with one third of affected children requiring intervention in early infancy. Increasing numbers of survivors combined with developmental expectations for independence, behavioral self-regulation and academic achievement have led to a growing identification of neurobehavioral symptoms in some survivors. A study now suggests that a cooling technique often used in heart operations does not impair neurological outcomes.

27 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

Isis Pharmaceuticals, Inc. announced today that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. ISIS-APOCIIIRx provides a novel approach to treat hypertriglyceridemia, or high levels of triglycerides (TG).

12 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

GIND scientists identify drug treatments that can normalize neuron development in AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aβ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains. What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aβ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.

4 Dec 2009

Research study compares genetic make-up of humans and primates

In spite of their genetic similarity to humans, chimpanzees and great apes have maximum lifespans that rarely exceed 50 years. The difference, explains USC Davis School of Gerontology Professor Caleb Finch, is that as humans evolved genes that enabled them to better adjust to levels of infection and inflammation and to the high cholesterol levels of their meat rich diets.

3 Dec 2009

Chronic hepatitis B seems to progress faster in men, report scientists

Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Their study has been published online in ACS' Journal of Proteome Research, a monthly publication.

19 Nov 2009

Gene-diet interaction influencing BMI and obesity replicated in three independent studies

Tufts University researchers have identified a gene-diet interaction that appears to influence body weight and have replicated their findings in three independent studies. Men and women carrying the CC genotype demonstrated higher body mass index (BMI) scores and a higher incidence of obesity, but only if they consumed a diet high in saturated fat. These associations were seen in the apolipoprotein A-II gene (APOA2) promoter.

18 Nov 2009

New neuroimaging techniques yield new insights on Alzheimer's disease

Brain imaging can offer a window into risk for diseases such as Alzheimer's disease (AD). A study conducted at the University of Kansas School of Medicine demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD. The results of this study are published in the November 2009 issue of the Journal of Alzheimer's Disease.

18 Nov 2009

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

Lipid assessment in vascular disease can be simplified by measuring cholesterol levels

Lipid assessment in vascular disease can be simplified by measuring either total and HDL cholesterol levels or apolipoproteins, without the need to fast and without regard to triglyceride levels, according to a study in the November 11 issue of JAMA.

11 Nov 2009

Alzheimer's disease research draws national attention

Research that is targeting the early diagnosis of Alzheimer disease has drawn national attention to the work of Michael Seidenberg, PhD, a faculty member at Rosalind Franklin University of Medicine and Science.

10 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Mirafit fbcx reduces human body absorption of consumed fat

A scientific study to be presented today at the annual meeting of The Obesity Society will confirm significant weight loss using the pill mirafit fbcx®. Dr. K-L Catherine Jen and Dr. Joseph Artiss, principals at ArtJen Complexus USA, LLC, will present these clinical study findings today, October 27, at The Obesity Society 2009 annual scientific meeting at the Marriott Wardman Park Hotel in Washington, D.C., The Obesity Society's 27th annual scientific meeting.

28 Oct 2009

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Edmonton - Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009

The biology of apoE and apoE receptors in Alzheimer's disease to be researched under new NIH program

A researcher at the University of Illinois at Chicago College of Medicine has been awarded more than $9.8 million to head a five-year National Institute on Aging Program Project Grant.

2 Sep 2009

Brain imaging (MRI/PET) bring us closer to earlier detection of Alzheimer's

Changes in the brain measured with MRI and PET scans, combined with memory tests and detection of risk proteins in body fluids, may lead to earlier and more accurate diagnosis of Alzheimer's, according to new research reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

14 Jul 2009

Atherotech receives patent for ApoB measurement for determining heart disease risk

Atherotech, Inc., developer of the VAP Cholesterol Test, has announced it has received a patent on its method to derive and report apolipoprotein B100 (apoB) using the Vertical Auto Profile (VAP) technology. The patent recognizes the unique ability of the VAP Cholesterol Test to accurately report apoB, the next milestone in heart disease risk assessment.

19 May 2009

Discovery of major new treatment target in diseased arteries

Removing a single protein prevents early damage in blood vessels from triggering a later-stage, frequently lethal complication of atherosclerosis, according to research published online today in the journal Nature Medicine. By eliminating the gene for a signaling protein called cyclophilin A (CypA) from a strain of mice, researchers were able to provide complete protection against abdominal aortic aneurysm (AAA).

11 May 2009

Diabetes and elevated levels of cholesterol linked to faster cognitive decline in Alzheimer's patients

A history of diabetes and elevated levels of cholesterol, especially LDL cholesterol, are associated with faster cognitive decline in patients with Alzheimer's disease, according to a new study from Columbia University Medical Center researchers.

10 Mar 2009